AbbVie’s deal team is having a busy week. Days after inking a $1.4 billion buyout, the drugmaker has put up the same again in biobucks to secure options on multispecific T-cell engagers from ...

Preclinical proof-of-concept data supports the potential of CD3 Switch-DARPin platform to activate and boost T cells in the presence of tumor ...

Blocking a protein that imports lactic acid, a metabolic byproduct of cancer cells, reinvigorated exhausted T cells and led to improved tumor control in mouse models of cancer, according to a new ...

VANCOUVER, British Columbia, November 07, 2024 -- ( BUSINESS WIRE )-- AbCellera (Nasdaq: ABCL) today announced new data on ...

AbbVie has entered into a partnership and option-to-license agreement with EvolveImmune Therapeutics, to develop ...

Some key published and presented research findings include: Adoptive T cell receptor (TCR ... a second CAR molecule improved tumor specificity and enhanced NK cell activity Adding CD28 costimulation ...

TCRclub integrates scRNA-seq and scTCR-seq data by local harmony to identify functionally similar T cell groups, termed ...

H-Y responses were elicited by intraperitoneal injection of 5 x 106 male spleen cells into female recipients. ELISpot Assay. IFN-γ-secreting T cells were enumerated using MultiScreen-IP ELISpot ...

Claudin-6 (CLDN6) is a tight junction protein that has been found to be up-regulated in around 20 different types of cancer, among them ovarian, endometrial and germ cell tumors. Conventional T-cell ...

Dolores Schendel, Chief Scientific Officer and Kirsty Crame, MD, Vice President, Clinical Strategy & Development Presentations and seminars highlighted Medigene’s proprietary End-to-End Platform for ...